Breaking News
December 10, 2018 - Scientists find answers to how cancer spreads
December 10, 2018 - Study explores why older people read more slowly
December 10, 2018 - Asbestos found in most NHS hospitals finds BBC inquiry
December 10, 2018 - Researchers use new technique to probe hydrogen bonds
December 10, 2018 - Music improves social communication in autistic children
December 10, 2018 - Some Brain Tumors May Respond to Immunotherapy, New Study Suggests
December 10, 2018 - Banning junk food ads to combat childhood obesity
December 10, 2018 - Skin Autofluorescence Predicts T2DM, Heart Disease, Mortality
December 10, 2018 - Largest autism sequencing study to date yields 102 genes associated with ASD
December 10, 2018 - Statins associated with low risk of side effects
December 10, 2018 - Study explores how schools address adolescent self-harming practices
December 10, 2018 - Pregnancy in adolescence linked to increased risks of complications in young mothers
December 10, 2018 - Risk Analysis publishes special issue on communicating about Zika virus
December 10, 2018 - Botox May Help Prevent Post-Op A-Fib
December 10, 2018 - African-American mothers rate boys higher for ADHD
December 10, 2018 - Graphic warning labels cancel out cigarettes’ appeal to young people
December 10, 2018 - Australian researchers to study gas inhalational anaesthetic and likelihood of cancer return
December 10, 2018 - Individual neurons located within the brain have implications for psychiatric diseases
December 10, 2018 - Researchers improve bariatric surgery scoring system to extend prediction time for diabetic remission
December 10, 2018 - HPV type 16 or 18 associated with cervical cancer risk in young women
December 10, 2018 - Cervical cancer risk is higher in women with positive HPV, but no cellular abnormalities
December 10, 2018 - Combo therapy not needed if low RA disease activity achieved
December 10, 2018 - Novel therapeutic targets based on biology of aging show promise for Alzheimer’s disease
December 10, 2018 - UC San Diego professor receives NCI Outstanding Investigator Award for cancer research
December 10, 2018 - Study evaluates placental mesenchymal stem cell sheets for myocardial repair and regeneration
December 10, 2018 - Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
December 10, 2018 - Study clarifies ApoE4’s role in dementia
December 10, 2018 - Eating disorders now a top priority with Australian Government
December 10, 2018 - Neuronal activity in the brain allows prediction of risky or safe decisions
December 10, 2018 - FDA Alerts Health Care Professionals and Patients Not to Use Drug Products Intended to be Sterile from Promise Pharmacy
December 10, 2018 - Improving dementia care and treatment saves thousands of pounds in care homes
December 10, 2018 - Heroin-assisted treatment can offer benefits, reduce harms
December 10, 2018 - People covered by Michigan’s expanded Medicaid program report improvements in health, finds study
December 10, 2018 - Hazelnuts improve micronutrient levels in older adults
December 9, 2018 - History of Partner Violence Tied to Menopause Symptoms
December 9, 2018 - Clean Up Safely After a Disaster|Natural Disasters and Severe Weather
December 9, 2018 - Drug wholesalers drove fentanyl’s deadly rise, report concludes
December 9, 2018 - Deprescribing could help manage polypharmacy in older adults
December 9, 2018 - Retraction of article “Joy of cooking too much” from journal
December 9, 2018 - FDA Warns of Rare Stroke Risk With MS Drug Lemtrada (Alemtuzumab)
December 9, 2018 - Feds say heroin, fentanyl remain biggest drug threat to US
December 9, 2018 - Eliminating microglia can reverse some aspects of stress sensitization, study shows
December 9, 2018 - New genetic insight could help treat rare debilitating heart and lung condition
December 9, 2018 - MiRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
December 9, 2018 - Work with your doctor to weigh pros, cons of treatment options for hyperthyroidism
December 9, 2018 - CWRU researcher secures $14.6 million funding for genetic study into Alzheimer’s disease
December 9, 2018 - High intensity statin treatment and adherence could save more lives
December 9, 2018 - Surgery patients use only 1/4 of prescribed opioids, and prescription size matters
December 9, 2018 - AXT offers Phi Optics upgrade to QPI systems for inverted light microscopes
December 9, 2018 - New booklet could help improve conditions of young pupils with albinism
December 9, 2018 - Few Physicians Work in Practices That Use Telemedicine
December 9, 2018 - Older Adults and Oral Health
December 9, 2018 - Health utility values improve after septorhinoplasty
December 9, 2018 - New EU-funded project provides insight into how the brain develops
December 9, 2018 - Expanded use of tele-emergency services can help strengthen rural hospitals
December 9, 2018 - Infections in the Young May Be Tied to Risk for Mental Illness: Study
December 9, 2018 - Profile: Native Hawaiians and Pacific Islanders
December 9, 2018 - Snoring poses greater cardiac risk to women
December 9, 2018 - Researcher takes further steps in understanding how and why cute aggression occurs
December 9, 2018 - Researchers create new light-activated tools for controlling neurons
December 9, 2018 - Spinal cord injury disrupts the body’s internal clock, study shows
December 9, 2018 - Babies recognize nested structures similar to our grammar
December 9, 2018 - UT Austin researcher receives $2.5 million CZI grant for neurodegenerative disease research
December 9, 2018 - Sleep problems found to be prevalent and increasing among college students
December 9, 2018 - Study reveals why some children are susceptible to the effects of maltreatment
December 9, 2018 - Study investigates influence of different opioids on driving performance
December 9, 2018 - Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
December 9, 2018 - Eliminating microglia prevents heightened immune sensitivity after stress
December 9, 2018 - Boys with social difficulties are at greatest risk of early substance use
December 9, 2018 - ‘Wrong’ connective tissue cells linked to worse prognosis in breast cancer patients
December 8, 2018 - Chronic, refractory schizophrenia patients benefit from targeted cognitive training
December 8, 2018 - Advertising in kids’ apps more prevalent than parents may realize
December 8, 2018 - New way to trace the transmission histories of rare genetic diseases
December 8, 2018 - ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
December 8, 2018 - Results of pediatric genomic epilepsy tests often reclassified
December 8, 2018 - New way of controlling HIV latency to completely eradicate the virus
December 8, 2018 - Phasefocus to showcase the Livecyte 2 at ASCB
December 8, 2018 - KHN’s ‘What the Health?’ Is health spending the next big political issue?
December 8, 2018 - Mussels take in microplastic pollution fibers and flush most of them out again
December 8, 2018 - AHA: How to Stop Smoking … for Good
LDR brachytherapy for treating early-stage prostate cancer lacks conclusive data

LDR brachytherapy for treating early-stage prostate cancer lacks conclusive data

image_pdfDownload PDFimage_print

Interstitial brachytherapy uses slightly radioactive particles implanted into the prostate to deliver radiation directly to the tumour (low-dose-rate, LDR). Due to a lack of conclusive data, it still remains an unresolved issue as to whether this procedure has advantages compared with other treatments in men with localized prostate cancer. This is the sobering conclusion reached in the rapid report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 16 November 2018.

About eleven years after its first benefit assessment and about seven years after a search update, the Institute again analysed current studies. In 2011, the Institute was very optimistic that gaps in knowledge could be closed before long as the self-administration in the German health care system had cleared the way for a large-scale German study in 2009. However, this study (PREFERE) was terminated prematurely in late 2016. Since there are no new data, the results of the earlier IQWiG assessments remain valid.

Comparison of therapy alternatives

Prostate cancer is potentially curable as long as the tumour is still confined to the prostate gland. Several options are available for the treatment of such a localized tumour: Besides complete surgical removal of the prostate (radical prostatectomy, RP) or radiation with an external radiation source (external beam radiotherapy, EBRT), permanent interstitial LDR brachytherapy offers another therapy option. In this treatment, small radioactive particles are permanently implanted in the prostate via specific needles to deliver radiation directly to the tumour.

As, even without treatment, prostate tumours either stop growing or grow very slowly in many patients, the fourth option to be considered is a specific form of watchful waiting called active surveillance.

Usable data from two new studies

In their current search, the researchers identified one additional randomized controlled trial (RCT), which compared LDR brachytherapy with prostatectomy (RP). The SPIRIT study was terminated prematurely, but IQWiG was able to include the data of the patients randomly allocated (34) up to that time point.

The results of three further newly included studies, all of which were prospective, comparative cohort studies, were only usable in one case. In this study, LDR brachytherapy was compared both with RP and with radiotherapy (EBRT).

In addition, a newer publication on a study that had already been included in the 2011 update was relevant for the current rapid report. This study also had three arms (LDR brachytherapy/RP/EBRT).

No statements on survival possible

The Institute could extract data on patient-relevant outcomes from these three sources. But none of them reported results on overall survival or on disease-free survival, hence the only outcomes referring to the cure of the disease.

In its current assessment, the Institute again did not use the data on the so-called PSA-based recurrence-free survival as this remains to be a non-validated surrogate.

As in the earlier assessments, it has not been proven that, compared with the alternative treatments, LDR brachytherapy is at least equivalent in respect of survival. It is therefore possible that patients who undergo LDR brachytherapy die earlier or have a shorter disease-free survival period.

Possible advantages in other treatment goals not interpretable

Regarding other outcomes, the results are partly in favour, partly to the disadvantage of LDR brachytherapy. There are indications that catheterization is required for a longer period of time than in EBRT. In contrast, brachytherapy seems to result in less impairment of sexual function than RP. With the persistent data gaps regarding survival, these results cannot be reliably classified, however. “As long as we do not know how reliably brachytherapy works against cancer, this does not suffice to speak of a benefit,” says Stefan Lange, IQWiG’s Deputy Director.

Various suspensions of G-BA consultations

The Federal Joint Committee (G-BA) commissioned a first benefit assessment in 2004. After the negative result of the first report, the topic was included in the agenda again in 2009. Since evidence was still lacking, the Committee initiated a large-scale study (PREFERE). The acronym reflected the intention to consider patient preferences in the study. An unprecedented concerted effort of the German Cancer Aid and the statutory health insurance funds secured study funding of up to 25 million euros.

In 2013, the G-BA decided to further suspend consultations until 2030, when the results of the PREFERE study would be available.

IQWiG very much welcomed this development: Instead of making decisions on an uncertain evidence base, in an exemplary fashion, the self-administration had provided the preconditions to close existing gaps in knowledge. “In any event this approach will improve the quality of health care of patients with early-stage prostate cancer,” states a 2011 press release.

False hopes

Yet it turned out differently: In late 2016, the study investigators announced the premature end of the PREFERE study. They had not succeeded in recruiting enough patients for participation. Stefan Lange calls this development “an embarrassment not only for the professional societies, but for the entire research and health care system”.

He adds: “The main reason why this unprecedented project, which was funded entirely without industrial sponsoring, failed was that too many of the parties involved lacked commitment. Some study centres did succeed in recruiting a sufficient number of patients for PREFERE. Hence, the study was principally feasible, even though interested expert groups denied this. Now we are almost where we were in 2004.”

Consequently, the G-BA resumed the consultations in 2017, and commissioned IQWiG with the update. Its decision will be based on the current rapid report with the conclusion: benefit unclear, reliable evidence is lacking.

Source:

https://www.iqwig.de/en/press/press-releases/benefit-of-ldr-brachytherapy-in-patients-with-early-stage-prostate-cancer-is-still-unclear.10524.html

Tagged with:

About author

Related Articles